Trial Profile

A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MP-0533 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Molecular Partners AG

Most Recent Events

05 Jun 2025 Planned number of patients changed from 75 to 249.
05 Jun 2025 Planned End Date changed from 1 Dec 2027 to 1 Dec 2029.
05 Jun 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com